Wall Street Analysts See a 229.34% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?

Group 1 - Nuvectis Pharma, Inc. (NVCT) closed at $6.68, with a 2.6% gain over the past four weeks, and has a mean price target of $22, indicating a 229.3% upside potential [1] - The mean estimate includes three short-term price targets with a standard deviation of $2.65, where the lowest estimate of $20 suggests a 199.4% increase, and the highest estimate of $25 indicates a 274.3% increase [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements [10][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 15.3% over the last 30 days, with two estimates moving higher and no negative revisions [11] - NVCT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [12] - While the consensus price target may not be a reliable indicator of the stock's potential gain, it does suggest a positive direction for price movement [12]